Clinical trial
Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
NCT01684163 is registered in ClinicalTrials.gov with Naurex, Inc, an affiliate of Allergan plc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder
- Lead sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2012
- Completion date
- June 30, 2014
- Enrollment
- 369 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.